Canada - English - Health Canada

hoffmann-la roche limited - emicizumab - solution - 150mg - emicizumab 150mg - antihemorrhagic agents, miscellaneous

Israel - English - Ministry of Health

truemed ltd, israel - emapalumab - concentrate for solution for infusion - emapalumab 5 mg / 1 ml - emapalumab - gamifant is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (hlh) with refractory, recurrent or progressive disease or intolerance with conventional hlh therapy.

Canada - English - Health Canada

astrazeneca canada inc - durvalumab - solution - 50mg - durvalumab 50mg - antineoplastic agents

Canada - English - Health Canada

sanofi-aventis canada inc - dupilumab - solution - 100mg - dupilumab 100mg

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - durvalumab 120mg;   - concentrate for infusion - active: durvalumab 120mg   excipient: histidine histidine hydrochloride monohydrate polysorbate 80 trehalose dihydrate water for injection - imfinzi (durvalumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: · have disease progression during or following platinum-containing chemotherapy · have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy this indication is approved based on objective response rate and duration of response in a single arm study. an improvement in survival or disease-related symptoms has not been established.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - durvalumab 500mg;   - concentrate for infusion - active: durvalumab 500mg   excipient: histidine histidine hydrochloride monohydrate polysorbate 80 trehalose dihydrate water for injection - imfinzi (durvalumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: · have disease progression during or following platinum-containing chemotherapy · have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy this indication is approved based on objective response rate and duration of response in a single arm study. an improvement in survival or disease-related symptoms has not been established.

Canada - English - Health Canada

sanofi-aventis canada inc - dupilumab - solution - 300mg - dupilumab 300mg - misc. skin and mucous membrane agents

Canada - English - Health Canada

sanofi-aventis canada inc - dupilumab - solution - 200mg - dupilumab 200mg - misc. skin and mucous membrane agents

Canada - English - Health Canada

sanofi-aventis canada inc - dupilumab - solution - 300mg - dupilumab 300mg - misc. skin and mucous membrane agents

Canada - English - Health Canada

sanofi-aventis canada inc - dupilumab - solution - 200mg - dupilumab 200mg